Select publications using tissue samples and resources from the St. Louis Breast Tissue Registry are highlighted below. Apply for full tissue sections or tissue microarrays.

Risom T, Glass DR, Averbukh I, Liu CC, Baranski A, Kagel A, McCaffrey EF, Greenwald NF, Rivero-Gutiérrez B, Strand SH, Varma S, Kong A, Keren L, Srivastava S, Zhu C, Khair Z, Veis DJ, Deschryver K, Vennam S, Maley C, Hwang ES, Marks JR, Bendall SC, Colditz GA, West RB, Angelo M. Transition to invasive breast cancer is associated with progressive changes in the structure and composition of tumor stroma. Cell. Volume 185, Issue 2, 2022, Pages 299-310.e18, ISSN 0092-8674, https://doi.org/10.1016/j.cell.2021.12.023.

Cho B, Han Y, Lian M, Colditz GA, Weber JD, Ma C, Liu Y. Evaluation of Racial/Ethnic Differences in Treatment and Mortality Among Women With Triple-Negative Breast Cancer. JAMA Oncol. 2021 May 13:e211254. doi: 10.1001/jamaoncol.2021.1254. Epub ahead of print. PMID: 33983438; PMCID: PMC8120441.

Kung CP, Cottrell KA, Ryu S, Bramel ER, Kladney RD, Bao EA, Freeman EC, Sabloak T, Maggi L Jr, Weber JD. Evaluating the therapeutic potential of ADAR1 inhibition for triple-negative breast cancer. Oncogene. 2021 Jan;40(1):189-202. doi: 10.1038/s41388-020-01515-5. Epub 2020 Oct 27. Erratum in: Oncogene. 2021 Mar;40(11):2147. PMID: 33110236; PMCID: PMC7796950.

Fox GC, Su X, Davis JL, Xu Y, Kwakwa KA, Ross MH, Fontana F, Xiang J, Esser AK, Cordell E, Pagliai K, Dang HA, Sivapackiam J, Stewart SA, Maher CA, Bakewell SJ Fitzpatrick JAJ, Sharma V, Achilefu S, Veis DJ, Lanza GM, Weilbaecher KN. Targeted Therapy to β3 Integrin Reduces Chemoresistance in Breast Cancer Bone Metastases. Mol Cancer Ther June 1 2021 (20) (6) 1183-1198; DOI: 10.1158/1535-7163.MCT-20-0931

Rozenblatt-Rosen O, Regev A, Oberdoerffer P, Nawy T, Hupalowska A, Rood J, Ashenberg O, Cerami E, Coffey RJ, Demir E, Ding L, Esplin ED, Ford JM, Goecks J, Ghosh S, Gray JW, Guinney J, Hanlon SE, Hughes SK, Hwang ES, Iacobuzio-Donahue CA, Jane-Valbuena J, Johnson BE, Lau KS, Lively T, Mazzilli SA, Pe’er D, Santagata S, Shalek AK, Schapiro D, Snyder MP, Sorger PK, Spira AE, Srivastava S, Tan K, West RB, Williams EH, Human Tumor Atlas Network. The Human Tumor Atlas Network: Charting Tumor Transitions Across Space and Time at Single-Cell Resolution. Cell. 2020 April; 181 (2): 236-249. doi: 10.1016/j.cell.2020.03.053

Lin CY, Vennam S, Purington N, Lin E, Varma S, Han S, Desa M, Seto T, Wang NJ, Stehr H, Troxell ML, Kurian AW, West RB. Genomic Landscape of Ductal Carcinoma in Situ and Association With Progression. Breast Cancer Research and Treatment. 2019 November; 178 (2): 307-316. doi: 10.1007/s10549-019-05401-x

Ademuyiwa F, Salyer P, Ma Y, Fisher S, Colditz G, Weilbaecher K, Bierut L. Assessing the effectiveness of the National Comprehensive Cancer Network genetic testing guidelines in identifying African American breast cancer patients with deleterious genetic mutations. Breast Cancer Research and Treatment. 2019; 178: 151-159. doi: 10.1007/s10549-019-05359-w

Yang C, Sun L, Zhang L, Zhou L, Niu D, Cao W, Li Z, Huang X, Kang Q, Jia L, Platik M, Liu X, Lai J, Cao D. SATB2 shows different profiles between appendiceal adenocarcinomas ex goblet cell carcinoids and appendiceal/colorectal conventional adenocarcinomas: an immunohistochemical study with comparison to CDX2. Gastroenterology Research.  2018;11(3):223-230.

Yang C, Sun L, Zhang L, Zhou L, Zhao M, Peng Y Niu D, Li Z, Huang X, Kang Q, Jia L, Lai J, Cao D. Diagnostic Utility of SATB2 in Metastatic Krukenberg Tumors of the Ovary: An Immunohistochemical Study of 70 Cases With Comparison to CDX2, CK7, CK20, Chromogranin, and Synaptophysin. Am J Surg Pathol. 2018 Feb;42(2):160-171. doi: 10.1097/PAS.0000000000000951.

Ross MH, Esser AK, Fox GC, Schmieder AH, Yang X, Hu G, Pan D, Su X, Xu Y, Novack DV, Walsh T, Colditz GA, Lukaszewicz GH, Cordell E, Novack JS, Fitzpatrick J, Waning DL, Mohammad KS, Guise TA, Lanza GM, & Weilbaecher KN. Bone-induced expression of integrin β3 enables targeted nanotherapy of breast cancer metastases. Cancer Research. 2017 Aug 30. DOI: 10.1158/0008-5472.CAN-17-1225.

Toriola AT, Dang HX, Hagemann IS, Appleton CM, Colditz GA, Luo J, & Maher CA. Increased breast tissue receptor activator of nuclear factor-κB ligand (RANKL) gene expression is associated with higher mammographic density in premenopausal women. Oncotarget. Epub 2017 May 16.

Miller CA, Gindin Y, Lu C, Griffith OL, Griffith M, Shen D, Hoog J, Li T, Larson DE, Watson M, Davies SR, Hunt K, Suman VJ, Snider J, Walsh T, Colditz GA, DeSchryver K, Wilson RK, Mardis ER, Ellis MJ. Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers. Nat Commun. 2016 Aug 9;7:12498. doi: 10.1038/ncomms12498. PubMed PMID: 27502118; PubMed Central PMCID: PMC4980485.

Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, Halushka MK, Sukumar S, Parker LM, Anderson KS, Harris LN, Garber JE, Richardson AL, Schnitt SJ, Nikolsky Y, Gelman RS, Polyak K. Molecular definition of breast tumor heterogeneity. Cancer Cell. 2007 Mar;11(3):259-73. PMID: 17349583.

Wu K, Li A, Rao M, Liu M, Dailey V, Yang Y, Di Vizio D, Wang C, Lisanti MP, Sauter G, Russell RG, Cvekl A, Pestell RG. DACH1 is a cell fate determination factor that inhibits cyclin D1 and breast tumor growth. Mol Cell Biol. 2006 Oct;26(19):7116-29.

Filardo EJ, Graeber CT, Quinn JA, Resnick MB, Giri D, Delellis RA, Steinhoff MM, Sabo E. Distribution of GPR30, a Seven Membrane-Spanning Estrogen Receptor, in Primary Breast Cancer and its Association with Clinicopathologic Determinants of Tumor Progression. Clin Cancer Res. 2006 Nov 1;12(21):6359-66. PMID: 17085646.

Henke RT, Eun Kim S, Maitra A, Paik S, Wellstein A. Expression analysis of mRNA in formalin-fixed, paraffin-embedded archival tissues by mRNA in situ hybridization. Methods. 2006 Apr;38(4):253-62. PMID: 16513366.

Portera CC, Yang SX, Wedam SB, Nguyen D, Vatas U, Takikita M, Hewitt SM, Liewehr DJ, Steinberg SM, Sherman M, Levine PH, Swain SM. Evaluation of E-cadherin expression and lymphatic involvement in inflammatory breast cancer. Session Info: Poster Session IV: Detection and Diagnosis: Diagnostic Pathology. SABCS 2006.

Perez EA. HER-2 as a Prognostic, Predictive, and Therapeutic Target in Breast Cancer. Cancer Control. 1999 May;6(3):233-240. PMID: 10758552.

Download more publications utilizing the St. Louis Breast Tissue Registry.